These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28895119)

  • 61. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.
    Zhong D; Xie Z; Huang B; Zhu S; Wang G; Zhou H; Lin S; Lin Z; Yang B
    Cell Physiol Biochem; 2018; 49(3):1163-1179. PubMed ID: 30196282
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
    Zhang Y; Wu B; Zhang H; Ge X; Ying S; Hu M; Li W; Huang Y; Wang L; Chen C; Shan X; Liang G
    J Cell Mol Med; 2018 Feb; 22(2):936-947. PubMed ID: 29077272
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment.
    Jena PK; Sheng L; Liu HX; Kalanetra KM; Mirsoian A; Murphy WJ; French SW; Krishnan VV; Mills DA; Wan YY
    Am J Pathol; 2017 Aug; 187(8):1800-1813. PubMed ID: 28711154
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice.
    Lee J; Seok S; Yu P; Kim K; Smith Z; Rivas-Astroza M; Zhong S; Kemper JK
    Hepatology; 2012 Jul; 56(1):108-17. PubMed ID: 22278336
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways.
    Weiss TS; Lupke M; Ibrahim S; Buechler C; Lorenz J; Ruemmele P; Hofmann U; Melter M; Dayoub R
    PLoS One; 2017; 12(9):e0184282. PubMed ID: 28877220
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.
    Hu YB; Liu XY; Zhan W
    Drug Des Devel Ther; 2018; 12():2213-2221. PubMed ID: 30038487
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression.
    Liu N; Meng Z; Lou G; Zhou W; Wang X; Zhang Y; Zhang L; Liu X; Yen Y; Lai L; Forman BM; Xu Z; Xu R; Huang W
    Mol Endocrinol; 2012 May; 26(5):775-85. PubMed ID: 22474109
    [TBL] [Abstract][Full Text] [Related]  

  • 69. SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice.
    Wen F; Bian D; Wu X; Liu R; Wang C; Gan J
    Chem Biol Drug Des; 2022 Mar; 99(3):504-511. PubMed ID: 35040254
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model.
    Zhang HM; Wang X; Wu ZH; Liu HL; Chen W; Zhang ZZ; Chen D; Zeng TS
    Mol Med Rep; 2016 Mar; 13(3):2135-42. PubMed ID: 26782298
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
    Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
    Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
    Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
    Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
    [TBL] [Abstract][Full Text] [Related]  

  • 74. FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs.
    Ramos Pittol JM; Milona A; Morris I; Willemsen ECL; van der Veen SW; Kalkhoven E; van Mil SWC
    Gastroenterology; 2020 Nov; 159(5):1853-1865.e10. PubMed ID: 32712104
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase.
    Shen LL; Liu H; Peng J; Gan L; Lu L; Zhang Q; Li L; He F; Jiang Y
    Mol Biol Rep; 2011 Jan; 38(1):553-9. PubMed ID: 20373033
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.
    Yan C; Zhang Y; Zhang X; Aa J; Wang G; Xie Y
    Biomed Pharmacother; 2018 Sep; 105():274-281. PubMed ID: 29860219
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
    Vignozzi L; Filippi S; Comeglio P; Cellai I; Sarchielli E; Morelli A; Rastrelli G; Maneschi E; Galli A; Vannelli GB; Saad F; Mannucci E; Adorini L; Maggi M
    Mol Cell Endocrinol; 2014 Mar; 384(1-2):143-54. PubMed ID: 24486698
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice.
    Li D; Zhang H; Zhong Y
    Biochem Biophys Res Commun; 2018 Apr; 498(3):388-394. PubMed ID: 28847729
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.
    Chow EC; Magomedova L; Quach HP; Patel R; Durk MR; Fan J; Maeng HJ; Irondi K; Anakk S; Moore DD; Cummins CL; Pang KS
    Gastroenterology; 2014 Apr; 146(4):1048-59. PubMed ID: 24365583
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.
    Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP
    Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.